Use of an intracardiac electrogram eliminates the need for a surface ECG during implantable cardioverter-defibrillator follow-up

被引:4
|
作者
Michael, Kevin A.
Peterson, Brett J.
Yue, Arthur M.
Wilson, Ryan D.
Wang, Li
Ousdigian, Kevin
Wilkoff, Bruce
Sterns, Laurence
Morgan, John M.
机构
[1] Southampton Gen Hosp, Wessex Cardiothorac Ctr, Southampton SO16 6YD, Hants, England
[2] Medtronic Inc, Minneapolis, MN USA
[3] Cleveland Clin Fdn, Cleveland, OH USA
[4] Royal Jubilee Hosp, Victoria, BC, Canada
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2007年 / 30卷 / 12期
关键词
defibrillation-ICD; electrocardiogram; new technology; pacing;
D O I
10.1111/j.1540-8159.2007.00888.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A surface electrocardiogram (SECG) for pacing threshold measurements during routine implantable cardioverter-defibrillator (ICD) follow-up can be cumbersome. This study evaluated the use of an intrathoracic far-field electrogram (EGM) derived between the Can and superior vena cava (SVC) electrode-the Leadless electrocardiogram (LLECG), in dual chamber ICDs in performing pacing threshold tests. Methods: The LLECG was evaluated prospectively during atrial and ventricular pacing threshold testing as a substudy of the Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators trial (EMPIRIC) in which dual chamber ICDs were implanted in 888 patients. Threshold tests were conducted at 1 volt by decrementing the pulse width. Follow-up at three months compared pacing thresholds measured using LLECG with those using Lead I of the surface ECG (SECG). The timesaving afforded by LLECG was assessed by a questionnaire. Results: The median threshold difference between LLECG and SECG measurements for both atrial (0.00 ms, P = 0.90) and ventricular (0.00 ms, P = 0.34) threshold tests were not significant. Ninety percent of atrial and ventricular threshold differences were bounded by +/- 0.10 ms and -0.10 to +0.04 ms, respectively. We found that 99% of atrial and ventricular thresholds tests at six and 12 months attempted using LLECG were successfully completed. The questionnaire indicated that 65% of healthcare professionals found LLECG to afford at least some timesaving during device follow-ups. Conclusion: Routine follow-up can be performed reliably and expeditiously in dual chamber Medtronic (Minneapolis, MN, USA) ICDs using LLECG alone, resulting in overall timesaving.
引用
收藏
页码:1432 / 1437
页数:6
相关论文
共 50 条
  • [31] Cardiac Sarcoidosis: Electrophysiological Outcomes on Long-Term Follow-Up and the Role of the Implantable Cardioverter-Defibrillator
    Mohsen, Amr
    Jimenez, Alejandro
    Hood, Robert E.
    Dickfeld, Timm
    Saliaris, Anastasios
    Shorofsky, Stephen
    Saba, Magdi M.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (02) : 171 - 176
  • [32] Long-Term Follow-Up of Implantable Cardioverter-Defibrillator for Secondary Prevention in Chagas' Heart Disease
    Martinelli, Martino
    de Siqueira, Sergio Freitas
    Sternick, Eduardo Back
    Rassi, Anis, Jr.
    Costa, Roberto
    Franchini Ramires, Jose Antonio
    Kalil Filho, Roberto
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (07): : 1040 - 1045
  • [33] Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome
    Bonny, Aime
    Tonet, Joelci
    Fontaine, Guy
    Frank, Robert
    EUROPEAN HEART JOURNAL, 2007, 28 (22) : 2819 - 2820
  • [34] High failure rate for an epicardial cardioverter-defibrillator lead: implications for long term follow-up of patients with an implantable cardioverter-defibrillator (vol 31, pg 616, 1998)
    Brady, PA
    Friedman, PA
    Trusty, JM
    Grice, S
    Hammill, SC
    Stanton, MS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) : 555 - 555
  • [35] Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy During Long-Term Follow-up of Patients With Coronary Artery Disease
    Blumer, Johannes
    Wolber, Thomas
    Hellermann, Jens
    Holzmeister, Johannes
    Binggeli, Christian
    Duru, Firat
    Brunckhorst, Corinna
    INTERNATIONAL HEART JOURNAL, 2009, 50 (03) : 313 - 321
  • [36] COMPLICATIONS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR THERAPY - FOLLOW-UP OF 241 PATIENTS
    GRIMM, W
    FLORES, BF
    MARCHLINSKI, FE
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1993, 16 (01): : 218 - 222
  • [37] Sophisticated remote implantable cardioverter defibrillator follow-up: A status report
    Schoenfeld, MH
    Reynolds, DW
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2005, 28 (03): : 235 - 240
  • [38] Submammary implantable cardioverter defibrillator with periareolar approach: technique and follow-up
    Ghiglieno, Chiara
    DellEra, Gabriele
    Occhetta, Eraldo
    Taveggia, Antonio
    Porcellini, Stefano
    Santagostino, Matteo
    Patti, Giuseppe
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0N) : N7 - N7
  • [39] Long-term follow-up of lead-related complications in 687 patients with implantable cardioverter-defibrillator
    Lighezan, D
    Hilbel, T
    Senges, J
    Becker, R
    Bauer, A
    Freigang, K
    Melkuomov, M
    Weretka, S
    Ruf-Richter, J
    Schoels, W
    EUROPEAN HEART JOURNAL, 2000, 21 : 121 - 121
  • [40] Prospective long-term follow-up of silicone-polyurethane-insulated implantable cardioverter-defibrillator leads
    Cairns, John A.
    Healey, Jeff S.
    Epstein, Andrew E.
    Themeles, Ellison
    Balasubramanian, Kumar
    Connolly, Stuart J.
    HEART RHYTHM O2, 2022, 3 (01): : 57 - 64